tiprankstipranks
Trending News
More News >
Genor Biopharma Holdings Limited (DE:67N0)
:67N0
Advertisement

Genor Biopharma Holdings Limited (67N0) Price & Analysis

Compare
0 Followers

67N0 Stock Chart & Stats


Genor Biopharma Holdings Limited News

67N0 FAQ

What was Genor Biopharma Holdings Limited’s price range in the past 12 months?
Genor Biopharma Holdings Limited lowest stock price was €0.14 and its highest was €0.50 in the past 12 months.
    What is Genor Biopharma Holdings Limited’s market cap?
    Genor Biopharma Holdings Limited’s market cap is €273.94M.
      When is Genor Biopharma Holdings Limited’s upcoming earnings report date?
      Genor Biopharma Holdings Limited’s upcoming earnings report date is Aug 27, 2025 which is 2 days ago.
        How were Genor Biopharma Holdings Limited’s earnings last quarter?
        Currently, no data Available
        Is Genor Biopharma Holdings Limited overvalued?
        According to Wall Street analysts Genor Biopharma Holdings Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Genor Biopharma Holdings Limited pay dividends?
          Genor Biopharma Holdings Limited does not currently pay dividends.
          What is Genor Biopharma Holdings Limited’s EPS estimate?
          Genor Biopharma Holdings Limited’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Genor Biopharma Holdings Limited have?
          Genor Biopharma Holdings Limited has 526,293,700 shares outstanding.
            What happened to Genor Biopharma Holdings Limited’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Genor Biopharma Holdings Limited?
            Currently, no hedge funds are holding shares in DE:67N0

            Company Description

            Genor Biopharma Holdings Limited

            Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company's principal drug candidates include GB242, an infliximab (Remicade) biosimilar for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric crohn's disease, and fistulising crohn's disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for treating hormone receptor-positive (HR+)/HER2- breast cancer and is under Phase III clinical trials; and GB492, a stimulator of interferon genes (STING) agonist expected to exert synergistic effects in combination with GB226 for solid tumors and is under Phase 1/2 clinical trial. Further, it develops GB221, a herceptin (trastuzumab)-mimic HER2 monoclonal antibody (mAb) drug candidate; geptanolimab (GB226), a novel PD-1 mAb drug candidate; GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb drug candidate, which is under Phase I clinical trial; and GB261 to treat B-cell non-Hodgkin Lymphoma and is under Phase I Clinical trials. In addition, the company's product candidates under clinical trials include GB262, GB264, GB265, and GB 266 for the treatment of cancer. Genor Biopharma Holdings Limited was formerly known as JHBP (CY) Holdings Limited and changed its name to Genor Biopharma Holdings Limited in June 2021. The company was founded in 2007 and is headquartered in Shanghai, China.

            Genor Biopharma Holdings Limited (67N0) Earnings & Revenues

            Similar Stocks
            Company
            Price & Change
            Follow
            TOT BIOPHARM International Co. Ltd.
            JW (Cayman) Therapeutics Co. Ltd.
            Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
            Zhaoke Ophthalmology Ltd.
            Immunotech Biopharm Ltd
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis